MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

Home・Akcijų sąrašas・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Atidarymo kaina

4.77

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

4.71

Max

4.77

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-10M -7.7M
Pardavimai	-10M 529K
Pelno marža	-1,463.516
Darbuotojai	44
EBITDA	-10M -7.7M

Dividendai
By Dow Jones
Kitas uždarbis	2026-03-26

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	28M 908M
Ankstesnė atidarymo kaina	4.77
Ankstesnė uždarymo kaina	4.77

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

3.255 / 3.365 Palaikymas ir pasipriešinimas

Arbutus Biopharma Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-02 22:45; UTC

Pagrindinės rinkos jėgos

GH Research Shares Up, Plans to Provide Update on New Drug Application

2026-01-04 23:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Rises Amid Geopolitical Risks After Maduro's Ouster -- Market Talk

2026-01-04 23:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Nikkei May Decline After Removal of Venezuela's Maduro -- Market Talk

2026-01-04 23:41; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Global Forex and Fixed Income Roundup: Market Talk

2026-01-04 23:40; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Markets Mostly Calm as Venezuelan Raid Weighed -- Market Talk

2026-01-04 23:35; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Declines on Oversupply Worries After Maduro's Ouster -- Market Talk

2026-01-04 23:19; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Global Energy Roundup: Market Talk

2026-01-04 23:19; UTC

Rinkos pokalbiai

Svarbiausios naujienos

ONGC Could Receive $500M in Unpaid Dividends From U.S. Takeover of Venezuelan Oil -- Market Talk

2026-01-04 23:17; UTC

Svarbiausios naujienos

Spot Gold Rises 0.8% to $4,365.24/oz

2026-01-04 23:16; UTC

Svarbiausios naujienos

Spot Gold Rises After U.S.' Removal of Venezuela's Maduro

2026-01-04 23:14; UTC

Svarbiausios naujienos

Front-Month WTI Crude Oil Futures Fall 0.6%; Front-Month Brent Crude Oil Futures Drop 0.5%

2026-01-04 23:13; UTC

Svarbiausios naujienos

Front-Month Crude Oil Futures Fall After Ouster of Venezuela's Maduro

2026-01-04 23:12; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Reliance Industries' Could Benefit from U.S. Takeover of Venezuelan Oil -- Market Talk

2026-01-04 22:37; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Can Gain From Flight to Quality, Central Bank Demand After Maduro Ouster -- Market Talk

2026-01-04 21:00; UTC

Uždarbis

An On-Time Jobs Report. Plus, Albertsons, Constellation, Jefferies, and More Stocks to Watch this Week. -- Barrons.com

2026-01-04 20:49; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Global Energy Roundup: Market Talk

2026-01-04 20:49; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Jitters About Potential for U.S. Actions Elsewhere Could Grow -- Market Talk

2026-01-03 18:59; UTC

Svarbiausios naujienos

Update: Trump Says U.S. Will 'Run' Venezuela After Maduro Is Flown to New York -- Barrons.com

2026-01-03 17:42; UTC

Svarbiausios naujienos

The Oil Sector's Biggest Winners and Losers From Venezuela Regime Change -- Barrons.com

2026-01-03 17:40; UTC

Svarbiausios naujienos

Trump Says U.S. Will 'Run' Venezuela After Maduro Is Flown to New York -- Barrons.com

2026-01-03 16:10; UTC

Svarbiausios naujienos

What Maduro's Capture Means for Chevron Stock -- Barrons.com

2026-01-03 15:53; UTC

Svarbiausios naujienos

Update: Venezuela's Maduro Captured by U.S. and Flown Out of Country, Trump Says -- Barrons.com

2026-01-03 15:03; UTC

Svarbiausios naujienos

Update: Venezuela's Maduro Captured by U.S. and Flown Out of Country, Trump Says -- Barrons.com

2026-01-03 14:10; UTC

Svarbiausios naujienos

Update: Venezuela's Maduro Captured by U.S. and Flown Out of Country, Trump Says -- Barrons.com

2026-01-03 12:16; UTC

Svarbiausios naujienos

U.S. Captures Maduro, Trump Says -- Barrons.com

2026-01-03 09:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2026-01-03 09:20; UTC

Rinkos pokalbiai

Uždarbis

Auto & Transport Roundup: Market Talk

2026-01-03 00:43; UTC

Įsigijimai, susijungimai, perėmimai

Research Reports -- Barrons.com

2026-01-02 22:13; UTC

Rinkos pokalbiai

Uždarbis

Tesla Seen As Quiet on Artificial-Intelligence Efforts -- Market Talk

2026-01-02 21:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Arbutus Biopharma Corp Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

Pirkti

Laikyti

Parduoti

Remiantis 0 analitikų, pateikusių Arbutus Biopharma Corp akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

3.255 / 3.365Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.